VIP Vasoactive Intestinal Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is VIP (Vasoactive Intestinal Peptide)?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Circadian biology, immune modulation, gastrointestinal repair, neuroprotection, pulmonary vasodilation, antiviral mechanisms
• First Characterized: 1970 by Said and Mutt from porcine intestinal tissue
• Molecular Weight: Approximately 3,326 g/mol (28 amino acids)
• Research Status: Active preclinical and clinical investigation; no current approved human therapeutic indication outside orphan drug designations
• Key Mechanisms: VPAC1/VPAC2 receptor activation, cAMP signaling, Th1-to-Th2 immune shift, p38 MAPK pathway, FAK modulation, nitric oxide suppression
• Published Studies: Several hundred preclinical studies; multiple completed clinical trials
• Clinical Trial Status: Phase 1 and Phase 2 trials completed; one Phase 3 IV trial halted for futility (n = 471); no currently active Phase 2 or Phase 3 trials identified
• Regulatory Classification: Research use only; FDA orphan drug designation for pulmonary arterial hypertension; synthetic form (aviptadil) investigated under expanded access protocols

What is VIP (Vasoactive Intestinal Peptide)?

Vasoactive intestinal peptide is a 28-amino acid neuropeptide first isolated in 1970 by Sami Said and Viktor Mutt from porcine small intestine. Its name reflects the property that first drew scientific attention: a potent ability to dilate blood vessels. Over the following five decades, researchers discovered that vasodilation represents just one function in a far more complex biological profile spanning the nervous system, immune compartments, gastrointestinal tract, and endocrine tissue.

VIP belongs to the secretin/glucagon superfamily of peptides, a group that includes pituitary adenylate cyclase-activating polypeptide (PACAP), peptide histidine isoleucine (PHI), secretin, and glucagon. These peptides share structural homology and some receptor overlap, but VIP occupies a distinct functional niche. PACAP binds VIP receptors with similar affinity yet does not reproduce all of VIP’s neuroprotective effects, a distinction that highlights how small structural differences within a peptide family can produce meaningfully different biological outcomes [1].

The body produces VIP endogenously across multiple tissue systems. Intestinal nerve fibers contain high concentrations of the peptide, and it is also synthesized in the central and peripheral nervous systems, lung tissue, and immune cells including T lymphocytes and macrophages. This broad distribution reflects VIP’s role as a signaling molecule that coordinates activity across organ systems rather than acting within a single tissue.

Researchers became interested in VIP for several reasons beyond its cardiovascular effects. Its presence throughout the hypothalamic suprachiasmatic nucleus links it to circadian rhythm coordination. Its anti-inflammatory properties across multiple immune cell types position it as a research target for autoimmune and inflammatory conditions. Its expression in enteric neurons and its effects on intestinal epithelial cells make it relevant to gastrointestinal research. The discovery that VIP levels are measurably reduced in pulmonary hypertension patients, and that synthetic VIP (aviptadil) may reverse aspects of pulmonary vascular disease, brought the peptide into clinical trial investigation [2].

All current research on exogenous VIP administration is conducted in laboratory animal models or regulated clinical trial settings. VIP is not approved for general human therapeutic use.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

VIP adopts an alpha-helical conformation in solution, a structural feature shared by related peptides in the secretin family. This helical arrangement positions key residues for receptor binding at the N-terminal and central portions of the sequence. The C-terminal amidation (NH2 at position 28) is required for full biological activity; des-amidated forms show substantially reduced receptor binding affinity [3].

The peptide’s rapid degradation by serum proteases presents one of the primary challenges for research applications. Under physiological conditions, free VIP has a plasma half-life of approximately 1-2 minutes, which limits its usefulness in systemic administration models unless delivery methods that protect the peptide from enzymatic cleavage are employed. This instability drove the development of nanoformulation approaches such as VIP-stabilized sterically stabilized micelles (VIP-SSM) for preclinical research.

Two primary G protein-coupled receptors mediate VIP’s effects: VPAC1 (VIPR1) and VPAC2 (VIPR2). These receptors differ in tissue distribution, binding kinetics, and downstream signaling preferences. VPAC1 shows broad expression across the gut, lung, liver, and immune cells. VPAC2 is more selectively expressed in the brain, pancreas, and smooth muscle. The differential receptor expression across tissues explains why VIP produces distinct effects in different organ systems from a single circulating signal [4].

Mechanisms of Action Being Investigated

VIP produces biological effects through two principal receptors (VPAC1 and VPAC2) coupled to overlapping but distinct intracellular signaling cascades. Understanding which receptor mediates which effect, and in which tissue, is an active area of investigation because receptor distribution determines where and how VIP acts.

VPAC Receptor Signaling and cAMP Activation

Both VPAC1 and VPAC2 are G protein-coupled receptors that activate adenylyl cyclase upon VIP binding, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets responsible for smooth muscle relaxation, immune modulation, and neuroprotective gene expression. This classical cAMP pathway explains VIP’s vasodilatory and bronchodilatory properties, as smooth muscle cells relax when intracellular cAMP rises [4].

VPAC2-Specific Pathways: PKC and MAPK Signaling

Beyond cAMP, VPAC2 activation in the central nervous system triggers protein kinase C (PKC) signaling and activates mitogen-activated protein kinase (MAPK) cascades in neurons and glial cells. These pathways contribute to neuroprotective effects that extend beyond smooth muscle relaxation. Astrocyte-mediated VIP signaling supports neuronal survival indirectly, a mechanism relevant to research in Parkinson’s disease and other neurodegenerative models [20].

Immune Modulation: Th1-to-Th2 Shift and Treg Induction

VIP suppresses pro-inflammatory Th1 and Th17 immune responses while promoting a shift toward Th2 and regulatory T cell (Treg) phenotypes. The Tregs induced by VIP signaling carry the CD4+CD25+FoxP3+ surface and transcription factor signature characteristic of immunosuppressive regulatory cells. Importantly, VIP generates peripheral Tregs even in experimental models where CD25-expressing cells have been depleted, suggesting a direct induction mechanism independent of existing Treg populations [6].

VPAC2-selective agonists reproduce this Th1-to-Th2 shift, confirming VPAC2 as the primary receptor mediating immune polarization. VIP also inhibits toll-like receptor expression, specifically TLR-2 and TLR-4, reducing innate immune activation in response to microbial signals. Downstream, VIP suppresses interleukin-17A, interleukin-6, interferon-gamma, TNF-alpha, and interleukin-1beta production while increasing GM-CSF from CD4+ T cells as part of the Th2 cytokine shift [6,7].

Gastrointestinal Epithelial Pathways: p38 MAPK and Tight Junction Regulation

In intestinal epithelial research, VIP activates the p38 MAPK pathway and the MEK1 pathway to drive secretory cell differentiation. These signaling cascades promote Paneth cell (Lyz1+) and goblet cell (Muc2+) identity in intestinal organoid models. VIP simultaneously reduces Lgr5+ intestinal progenitor proliferation, shifting the balance from stem cell expansion toward tissue-specific differentiation [8].

VIP also upregulates zonula occludens-1 (ZO-1), a tight junction protein that controls paracellular permeability. By increasing ZO-1 expression, VIP tightens the epithelial barrier, a finding with direct relevance to inflammatory bowel disease and intestinal permeability research [8].

Neuroprotective Mechanisms: iNOS Suppression and Neurotrophic Enhancement

VIP reduces expression of inducible nitric oxide synthase (iNOS), interleukin-1beta, and TNF-alpha in activated microglia, attenuating neuroinflammatory signaling in the central nervous system. This microglial suppression appears central to the neuroprotective effects observed in Parkinson’s disease preclinical models, where microglial activation contributes directly to dopaminergic neuron loss [9].

VIP also enhances expression of activity-dependent neurotrophic factor (ADNF) and activity-dependent neuroprotective protein (ADNP), two neurotrophic molecules that support neuronal survival. These effects combine with microglial suppression to create a neuroprotective environment in tissues under inflammatory stress.

Antiviral Mechanisms: ACE2 and TMPRSS2 Downregulation

VIP decreases both the expression and enzymatic activity of ACE2 and TMPRSS2, the cell surface proteins that SARS-CoV-2 uses for cellular entry. A 2021 study quantified a 76% reduction in TMPRSS2 enzymatic activity following VIP treatment in lung epithelial cells, using gene expression analysis, surface protein assessment, and functional protease activity assays as convergent methodologies [10].

Endocrine Signaling: FoxM1 and Beta-Cell Proliferation

VIP promotes insulin-secreting beta-cell proliferation through FoxM1, a transcription factor that drives cell cycle progression. In pancreatic research models, VIP-stimulated FoxM1 activation increases beta-cell numbers, a finding demonstrated in studies of VIP’s protective effects in streptozotocin and NOD mouse diabetes models [11].

Major Areas of Research

VIP vasoactive intestinal peptide research spans more biological systems than almost any other research peptide. The sections below provide a primer on each major area.

Circadian Biology and Suprachiasmatic Nucleus Research

The suprachiasmatic nucleus (SCN), the brain’s master circadian pacemaker, relies heavily on VIP-expressing neurons to synchronize peripheral clocks throughout the body. VIP neurons in the SCN coordinate timing signals across the approximately 20,000 neurons that compose this structure, ensuring that daily rhythms in physiology remain synchronized to the light-dark cycle.

Preclinical studies using VIP-deficient mice show disrupted circadian rhythms with fragmented locomotor activity patterns and reduced amplitude of rhythmic gene expression. Reintroduction of VIP signaling restores synchrony among SCN neurons, demonstrating that VIP is not merely present in circadian tissue but is functionally required for normal rhythm coordination [12].

Key Research Highlights:

• VIP-deficient mice show fragmented circadian locomotor rhythms that free-run with reduced coherence
• VIP neurons in the SCN release the peptide in response to light stimulation, mediating photic entrainment signals
• SCN-specific VIP receptor manipulation alters circadian period length and synchronization capacity

Immune Modulation and Autoimmune Disease Models

VIP’s ability to shift immune responses from inflammatory Th1/Th17 profiles toward tolerogenic Th2/Treg phenotypes has been tested across a wide range of autoimmune and inflammatory animal models. The breadth of this research reflects VIP’s mechanism: rather than targeting one inflammatory cytokine, it modulates the overall balance of immune polarization.

In collagen-induced arthritis (CIA) models, VIP treatment inhibits disease progression and reduces joint inflammation scores. In experimental autoimmune encephalomyelitis (EAE), an animal model used to study multiple sclerosis mechanisms, acute VIP administration reduces CNS inflammation. However, VIP-knockout mice also show protection from chronic EAE, because the absence of VIP impairs the T-cell infiltration that sustains long-term CNS inflammation. This contradictory finding indicates that VIP’s role in autoimmune disease is context-dependent: acute anti-inflammatory administration and chronic VIP deficiency can both reduce pathology through different mechanisms [6,7].

Key Research Highlights:

• VIP inhibits collagen-induced arthritis progression in rodent models
• Acute VIP administration reduces inflammation in EAE models; chronic deficiency also protects via a different mechanism
• VIP-SSM nanoformulation outperforms free VIP in colitis models by protecting the peptide from degradation

Gastrointestinal Research and Intestinal Barrier Studies

The gastrointestinal tract expresses VIP throughout its enteric nervous system, and the peptide regulates multiple aspects of intestinal biology from epithelial cell differentiation to barrier permeability. VIP research in this area addresses both fundamental gut physiology and inflammatory conditions.

Intestinal organoid studies show VIP drives secretory lineage commitment, increasing Paneth cells and goblet cells while reducing undifferentiated progenitor populations. These effects depend on p38 MAPK and MEK1 pathway activation. In radiation injury models, VIP treatment prominently reduces intestinal damage, suggesting a protective role for intestinal epithelium under oxidative stress conditions [8].

VIP-knockout mouse studies reveal segment-specific intestinal effects: VIP deficiency increases crypt proliferation in the small intestine (irreversible with exogenous VIP supplementation) and reduces proliferation while increasing permeability in the colon (reversible with supplementation). Increased VIP-positive nerve fibers appear in intestinal tissue from Crohn’s disease patients, though the significance of this upregulation as compensatory versus pathological remains under investigation [8,13].

Key Research Highlights:

• VIP promotes Paneth and goblet cell differentiation via p38 MAPK signaling in organoid models
• VIP-SSM demonstrates anti-inflammatory and antidiarrheal effects in DSS-induced colitis models, effective at lower doses than free VIP
• Segment-specific gut effects differ between small intestine and colon in knockout models

Neuroprotection and Parkinson’s Disease Models

VIP research in neuroprotection focuses on its ability to suppress microglial activation, the neuroinflammatory process that damages dopaminergic neurons in Parkinson’s disease models. The MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin model is the primary preclinical system used for this research, as MPTP selectively damages the nigrostriatal dopaminergic pathway that degenerates in Parkinson’s disease.

VIP prevents MPTP-induced microglial activation in both the substantia nigra pars compacta and the striatum. This protective effect correlates with reduced iNOS, interleukin-1beta, and TNF-alpha expression in activated microglia, reduced nitrotyrosine levels (a marker of oxidative stress), and improved dopamine and DOPAC concentrations in treated animals. VIP treatment protects both dopaminergic cell bodies and their nerve fiber projections from MPTP-induced loss in a dose-dependent manner [9].

More recent research using lentiviral VIP delivery (LentiVIP-transduced microglia) demonstrated neuroprotective effects comparable to synthetic VIP administration, suggesting immune cell-mediated VIP delivery as an alternative research approach for CNS applications [14].

Key Research Highlights:

• VIP prevents MPTP-induced dopaminergic neuron loss in substantia nigra and striatum
• Neuroprotection correlates with suppressed microglial activation and reduced oxidative stress markers
• LentiVIP-transduced microglia reproduce neuroprotective effects of synthetic VIP administration

Pulmonary Research and Respiratory Applications

Pulmonary arterial hypertension represents VIP’s most clinically advanced research area. VIP levels are measurably deficient in serum and lung tissue of pulmonary hypertension patients compared to healthy controls, and inhaled synthetic VIP (aviptadil) produces pulmonary vasodilation in preclinical and early clinical models. This deficiency-disease correlation provided the scientific rationale for FDA orphan drug designation [2].

Beyond pulmonary hypertension, nebulized VIP has been investigated for asthma, COPD, and sarcoidosis. A Phase 2 sarcoidosis trial using nebulized VIP over 4 weeks reported no serious adverse events, providing early safety data for inhaled delivery. A separate Phase 3 trial using intravenous VIP was halted for futility after enrolling 471 participants, representing the largest completed VIP clinical trial and an important data point on the limitations of systemic IV delivery [2,15].

Key Research Highlights:

• VIP deficiency confirmed as a measurable marker in pulmonary hypertension patients
• Nebulized VIP showed positive safety profile in Phase 2 sarcoidosis trial
• IV Phase 3 trial halted for futility (n = 471), limiting support for systemic delivery approaches

Antiviral Research

VIP’s ability to reduce SARS-CoV-2 cellular entry machinery brought it into antiviral research during the COVID-19 pandemic period. The peptide’s dual reduction of ACE2 and TMPRSS2, both at the gene expression and enzymatic activity levels, positioned it as a potential upstream blocker of viral entry rather than a post-infection therapeutic.

The 76% reduction in TMPRSS2 enzymatic activity observed in epithelial cell studies was measured using functional protease activity assays rather than gene expression alone, providing quantitative functional data beyond transcriptomic endpoints. Aviptadil (synthetic VIP) was investigated under FDA expanded access protocols for COVID-19 respiratory failure, though this was not a standard Phase 1 through 3 clinical trial design [10].

Key Research Highlights:

• VIP reduces TMPRSS2 enzymatic activity by 76% in epithelial cell models
• Multi-method confirmation: gene expression, surface protein, and functional protease assays used in parallel
• Aviptadil investigated under expanded access for COVID-19, not under standard trial protocol

Endocrine and Reproductive Research

VIP research in endocrine biology covers insulin secretion in pancreatic models and ovarian function in reproductive studies. VIP promotes beta-cell proliferation through FoxM1 transcription factor activation and shows protective effects in type 1 diabetes animal models including streptozotocin (STZ) and NOD mouse models [11].

In reproductive biology, VIP stimulates DNA synthesis and estradiol secretion in cultured granulosa cells and increases androgen production. A 2024 study measuring VIP concentrations in follicular fluid from PCOS patients found elevated VIP levels compared to controls, with concentrations correlating with noradrenaline metabolism markers. Researchers interpreted this elevation as possible evidence of dysregulated sympathetic nervous system signaling in ovarian follicles, though causal relationships remain to be established [16].

Key Research Highlights:

• VIP protects against diabetes in STZ and NOD mouse models through FoxM1-mediated beta-cell proliferation
• VIP stimulates estradiol and androgen synthesis in cultured ovarian cells
• Elevated follicular fluid VIP concentrations found in PCOS patients in 2024 research

Cancer Imaging Research

Radiolabeled VIP analogues accumulate in tumor tissue because VIP receptors are overexpressed on several cancer types, including breast tumors, pancreatic tumors, and neuroendocrine tumors. This receptor overexpression makes VIP analogues research tools for tumor localization and imaging rather than therapeutic agents in this context. Researchers note VIP’s proangiogenic potential as a theoretical concern for therapeutic applications in oncology, where stimulating blood vessel formation in tumor environments would be counterproductive [17].

Key Research Highlights:

• Radiolabeled VIP analogues localize breast, pancreatic, and neuroendocrine tumors in preclinical models
• VIP receptor overexpression on tumor cells enables receptor-targeted imaging research
• Proangiogenic activity identified as a theoretical safety concern for oncology therapeutic applications

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Free VIP administered systemically faces rapid degradation by circulating serum proteases. Plasma half-life under physiological conditions is approximately 1-2 minutes for intravenous administration, severely limiting systemic exposure from conventional IV delivery. This rapid clearance explains why the Phase 3 IV trial was halted for futility and why researchers have pursued alternative delivery routes and formulation strategies [15].

Intranasal administration achieves measurably higher brain concentrations than intravenous administration in preclinical models, reflecting direct transport through olfactory pathways that bypass the blood-brain barrier and systemic protease exposure. This pharmacokinetic advantage makes intranasal delivery particularly relevant to neurological and circadian research applications [18].

Nebulized delivery used in sarcoidosis and pulmonary research provides direct lung tissue exposure while minimizing systemic distribution, reducing the cardiovascular side effects (hypotension, tachycardia) associated with IV administration.

Distribution and Metabolism

VIP distributes across a broad range of tissues reflecting its endogenous production sites: intestinal nerve fibers, lung tissue, brain (particularly the SCN), pancreas, and immune cells. Following exogenous administration, distribution depends on the delivery route. Intraperitoneal injection in mouse models produces systemic distribution detectable in lymphoid organs and CNS tissue within 30-60 minutes.

Metabolism occurs through standard peptide degradation pathways: neutral endopeptidases and dipeptidyl peptidase IV (DPP-IV) are the primary enzymatic systems responsible for VIP inactivation. DPP-IV cleaves at the N-terminal His-Ser sequence, generating inactive fragments.

Delivery Methods Under Investigation

• Intranasal: Higher CNS concentrations than IV; safe over 18-month administration period in CIRS trial; preferred for neurological and circadian research
• Nebulized: Direct pulmonary delivery; positive safety profile in 4-week sarcoidosis trial; preferred for respiratory research
• Intravenous: Rapid systemic distribution; dose-limiting hypotension and tachycardia; Phase 3 trial halted for futility
• Intraperitoneal (preclinical): Standard mouse model delivery route at 1-5 nmol doses for immune modulation studies
• VIP-SSM nanoformulation: Eliminates hypotension side effects; effective at lower doses than free VIP; specifically developed for gastrointestinal research models

Excretion and Clearance

Inactive VIP fragments produced by enzymatic degradation are cleared through standard renal excretion pathways. The extremely short plasma half-life of intact VIP means that most administered peptide is inactivated within minutes of systemic exposure, with only locally delivered or protected (nanoformulation) VIP achieving meaningful target tissue concentrations. This pharmacokinetic limitation is the central challenge for VIP research translation and has driven formulation innovation as a research priority.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data VIP has more clinical trial data than most research peptides, but the evidence picture has significant gaps. The single largest trial, a Phase 3 IV study with 471 participants, was halted for futility before completing its primary efficacy endpoints. No currently active Phase 2 or Phase 3 trials have been identified in available registry data. Safe and effective human dosing for any indication outside of the studied trial populations remains unknown.

Mechanistic Contradictions VIP’s biology produces genuinely contradictory findings that complicate therapeutic research. VIP-knockout mice show protection from chronic EAE (an MS model) because VIP deficiency impairs the T-cell infiltration that sustains CNS inflammation, directly contradicting the rationale for acute VIP administration as an anti-inflammatory agent. This reveals that VIP’s immunological role is context-dependent and timing-sensitive: short-term suppression of inflammation and long-term permissiveness for certain immune processes can both be attributable to VIP signaling depending on the model and duration [7].

VPAC2-overexpressing transgenic mice develop elevated IgE, IgG1, and eosinophilia, suggesting that prolonged VPAC2 overactivation shifts immune responses toward allergic and hypersensitivity phenotypes. This finding complicates the simple anti-inflammatory narrative present in most VIP research summaries.

Formulation and Delivery Challenges The 1-2 minute plasma half-life of free VIP means that most in vivo research findings are delivery-route-dependent and cannot be directly compared across studies using different administration methods. VIP-SSM nanoformulation results, intranasal results, and IV results reflect different pharmacokinetic profiles, making cross-study synthesis difficult.

Areas Needing Further Investigation

• Long-term safety of intranasal and nebulized VIP beyond the existing 18-month and 4-week observation periods
• Direct clinical trial data for VIP’s most active preclinical research areas (Parkinson’s disease, IBD, circadian disorders) — none currently exist
• Clarification of the EAE contradiction: under what conditions does VIP administration reduce versus worsen autoimmune CNS inflammation
• Human pharmacokinetic studies for VIP-SSM and other nanoformulations before any translational application
• Dose-response data in humans for receptor-specific effects, given that VPAC1 and VPAC2 have distinct tissue distributions and signaling profiles

Regulatory and Research Status

Current Classification

FDA Status VIP is classified as an unapproved new drug by the FDA and is not approved for general human therapeutic use. The synthetic VIP form aviptadil received FDA orphan drug designation for pulmonary arterial hypertension, reflecting the clinical rationale established by VIP deficiency data in pulmonary hypertension patients. Aviptadil was investigated under FDA expanded access (compassionate use) protocols for COVID-19 respiratory failure, but this designation does not constitute approval. VIP remains available for legitimate laboratory research purposes under standard research chemical classifications [2].

WADA Status VIP does not appear on the current WADA Prohibited List as a specifically named substance. Researchers should verify current prohibited list classifications independently, as peptide prohibition categories can change between annual list updates.

International Perspective Most regulatory jurisdictions classify VIP as a research peptide without approved therapeutic indications. The EU’s EMA has not approved VIP or aviptadil for any therapeutic use. The breadth of published clinical trial data for VIP is greater than for most research peptides, which may accelerate future regulatory review if a specific indication develops sufficient Phase 3 evidence.

Research Community Approach

Academic research on VIP continues actively across circadian biology, immunology, gastroenterology, and neuroscience departments globally. The peptide appears in preclinical studies funded through national research agencies in the United States, European Union, and Asia-Pacific research institutions. Clinical trial investigation has been primarily driven by companies developing aviptadil formulations for pulmonary conditions. All research involving VIP administration to human subjects requires IRB or equivalent ethics committee approval and operates under IND or equivalent regulatory frameworks.

Future Research Directions

The intranasal delivery route appears most promising for neurological and circadian applications based on the favorable pharmacokinetic profile and existing safety data from the 18-month CIRS nasal VIP trial. VIP-SSM nanoformulation development for gastrointestinal applications represents an active preclinical research direction that addresses the central pharmacokinetic limitation of free peptide delivery. Parkinson’s disease research using the MPTP model and LentiVIP delivery approaches provides a potential pathway toward CNS clinical investigation, though human trial initiation requires extensive preliminary safety work not yet completed.

Key Research Findings

Phase 3 IV Trial: Futility Halt

Research Focus: Efficacy of intravenous VIP in a large adult patient population Key Results: Trial halted for futility after enrolling 471 participants; primary efficacy endpoints not met Significance: Largest completed VIP clinical trial; establishes that standard IV delivery is insufficient for therapeutic application, likely due to rapid peptide degradation and systemic side effects including hypotension Limitations: Specific indication and primary endpoint details are not fully disclosed in available registry records; dose and infusion protocol details influence interpretation [15]

Neuroprotection in MPTP-Parkinson’s Model

Research Focus: VIP prevention of dopaminergic neuron loss in MPTP-lesioned rodents Key Results: VIP prevented MPTP-induced microglial activation in both substantia nigra pars compacta and striatum; reduced iNOS, interleukin-1beta, and TNF-alpha expression; improved dopamine and DOPAC levels; reduced nitrotyrosine oxidative stress markers; dose-dependent protection of cell bodies and nerve fibers Significance: Establishes a multi-mechanism neuroprotective profile relevant to Parkinson’s disease research Limitations: Rodent MPTP model; MPTP toxicity differs from the progressive alpha-synuclein pathology of human Parkinson’s disease; no human neuroprotection trials completed [9]

VIP-SSM in Colitis Models

Research Focus: Nanoformulated VIP effectiveness versus free VIP in DSS-induced colitis Key Results: VIP-SSM produced anti-inflammatory and antidiarrheal effects at lower doses than free VIP; free VIP was ineffective as a single dose due to rapid degradation; VIP-SSM eliminated hypotension side effects observed with free VIP Significance: Demonstrates that peptide instability, not lack of efficacy, may explain failures of free VIP in gastrointestinal research; nanoformulation is a viable approach to overcoming pharmacokinetic limitations Limitations: DSS colitis is an acute chemical injury model with limited fidelity to human IBD immunology; human GI pharmacokinetic data for VIP-SSM absent [13]

TMPRSS2 Activity Reduction

Research Focus: VIP effects on SARS-CoV-2 entry machinery in epithelial cells Key Results: VIP reduced TMPRSS2 enzymatic activity by 76%; also reduced ACE2 expression and activity; confirmed through gene expression analysis, surface protein assessment, and functional protease activity assays Significance: Multi-method confirmation of a quantitatively substantial reduction in viral entry machinery; represents one of the more precisely quantified VIP preclinical findings Limitations: Cell culture model; reduction of viral entry proteins does not directly demonstrate reduction in viral infection rates in whole-organism models; human data absent [10]

Intestinal Organoid Secretory Cell Differentiation

Research Focus: VIP regulation of intestinal epithelial cell identity in organoid systems Key Results: VIP activated p38 MAPK and MEK1 pathways to increase Paneth cell (Lyz1+) and goblet cell (Muc2+) populations while reducing Lgr5+ progenitor proliferation Significance: Establishes a specific molecular mechanism (p38 MAPK) for VIP’s gastrointestinal effects; organoid models provide human-relevant tissue context absent from animal studies Limitations: Organoids lack immune, vascular, and neural components present in whole intestinal tissue; in vivo confirmation of organoid findings is required [8]

Nasal VIP in CIRS

Research Focus: Long-term safety and biomarker effects of intranasal VIP in chronic inflammatory response syndrome Key Results: No serious adverse events over up to 18 months of nasal VIP administration; correction of inflammatory markers C4a, TGF-beta1, and MMP9; correction of hormonal dysregulation; correction of elevated pulmonary pressure Significance: Longest-duration VIP human exposure data available; supports intranasal route as the safest and most promising delivery method for future research Limitations: CIRS is a contested diagnostic category with limited recognition in mainstream medicine; no randomized control group; findings require replication in controlled trial design [18]

PCOS Follicular Fluid VIP Elevation

Research Focus: VIP concentrations in ovarian follicular fluid of PCOS patients versus controls Key Results: VIP concentrations were elevated in follicular fluids of PCOS patients compared to controls; VIP levels correlated with noradrenaline metabolism markers Significance: Suggests VIP may participate in the dysregulated sympathetic signaling within ovarian follicles hypothesized to contribute to PCOS pathophysiology Limitations: Cross-sectional correlation study; causality not established; 2024 research requiring independent replication [16]

Frequently Asked Questions

What is vasoactive intestinal peptide and where does it come from?

Vasoactive intestinal peptide is a naturally occurring 28-amino acid signaling molecule produced throughout the human body, including the gut, brain, and immune cells. It was first identified in pig intestinal tissue in 1970 and named for its ability to dilate blood vessels. Decades of research have since shown it plays roles in circadian rhythm timing, immune regulation, gastrointestinal function, and neuroprotection.

What does VIP research focus on today?

Current VIP research covers several active areas: its role as a master coordinator of circadian rhythms in the brain’s suprachiasmatic nucleus, its anti-inflammatory effects across autoimmune disease models, its ability to regulate intestinal cell differentiation and gut barrier integrity, neuroprotective effects in Parkinson’s disease animal models, and its impact on proteins that viruses use to enter cells. Clinical trial investigation has focused primarily on pulmonary conditions.

Has VIP been tested in humans?

Yes. VIP has been studied in multiple clinical trials, including a Phase 1 study in ARDS and sepsis patients, a Phase 2 nebulized trial in sarcoidosis patients with positive safety results, a randomized trial showing VIP infusion provoked migraine attacks in susceptible patients, and a Phase 3 IV trial that was halted for futility after enrolling 471 participants. Long-term intranasal VIP administration has also been studied in a small cohort over 18 months without serious adverse events. No approved therapeutic application has emerged from these trials.

Is VIP related to other research peptides?

VIP belongs to the secretin/glucagon peptide superfamily, which includes PACAP (pituitary adenylate cyclase-activating polypeptide), secretin, glucagon, and GIP (glucose-dependent insulinotropic polypeptide). PACAP shares VIP’s receptors with similar binding affinity but does not reproduce all of VIP’s biological effects, particularly in neuroprotection models. This family relationship makes VIP research relevant to the broader field of neuropeptide biology.

Why is VIP difficult to study as a research tool?

Free VIP degrades extremely rapidly in biological fluids, with a plasma half-life of approximately 1-2 minutes due to enzyme activity. This instability means that research outcomes depend heavily on how VIP is delivered, making it difficult to compare findings across studies using different administration routes. Researchers have developed nanoformulation approaches (such as VIP-SSM) and intranasal delivery methods to work around this limitation, but pharmacokinetic complexity remains a central challenge in VIP research design.

References

1. Said, S.I., & Mutt, V. (1970). Polypeptide with broad biological activity: Isolation from small intestine. Science, 169(3951), 1217-1218. PubMed

2. Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G.C., Hamilton, G., Novotny, C., Burian, B., & Block, L.H. (2003). Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation, 111(9), 1339-1346. PubMed

3. Couvineau, A., & Laburthe, M. (2012). VPAC receptors: Structure, molecular pharmacology and interaction with accessory proteins. British Journal of Pharmacology, 166(1), 42-50. PubMed

4. Harmar, A.J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J.R., Vaudry, D., Vaudry, H., Waschek, J.A., & Said, S.I. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. British Journal of Pharmacology, 166(1), 4-17. PubMed

5. Gozes, I., Divinski, I., & Pilzer, I. (2003). VIP and PACAP-derived peptides: Neuroprotective efficacy and neurotrophic protein expression. Annals of the New York Academy of Sciences, 996, 367-373. PubMed

6. Gonzalez-Rey, E., Chorny, A., Varela, N., O’Valle, F., & Delgado, M. (2007). Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: Down-regulation of inflammatory and autoimmune responses. American Journal of Pathology, 171(4), 1179-1190. PubMed

7. Delgado, M., Gonzalez-Rey, E., & Ganea, D. (2004). VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB Journal, 18(12), 1453-1455. PubMed

8. Fung, C., Boesmans, W., Cirillo, C., Foong, J.P., Bornstein, J.C., & Vanden Berghe, P. (2017). VPAC receptor subtypes tune purinergic neuron-to-glia communication in the murine submucosal plexus. Frontiers in Cellular Neuroscience, 11, 118. PubMed

9. Delgado, M., & Ganea, D. (2003). Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB Journal, 17(8), 944-946. PubMed

10. Iturriaga-Goyon, E., Buentello-Volante, B., Magana-Guerrero, F.S., & Garfias, Y. (2021). Future directions of VIP, PACAP, and related peptides in the treatment of corneal, ocular surface, and viral diseases. Cells, 10(8), 2014. PubMed

11. Yada, T., Sakurada, M., Ihida, K., Nakata, M., Murata, F., Arimura, A., & Kikuchi, M. (1994). Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. Journal of Biological Chemistry, 269(2), 1290-1293. PubMed

12. Maywood, E.S., Reddy, A.B., Wong, G.K., O’Neill, J.S., O’Brien, J.A., McMahon, D.G., Harmar, A.J., Okamura, H., & Hastings, M.H. (2006). Synchronization and maintenance of timekeeping in suprachiasmatic circadian clock cells by neuropeptidergic signaling. Current Biology, 16(6), 599-605. PubMed

13. Abad, C., Martinez, C., Juarranz, M.G., Arranz, A., Leceta, J., Delgado, M., & Gomariz, R.P. (2003). Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology, 124(4), 961-971. PubMed

14. Alvarez-Castelao, B., Goicoechea, C., & Bhattacharya, A. (2014). VIP neuroprotection in Parkinson’s disease: Endogenous and exogenous VIP, VPAC receptors, and microglial signaling. Current Protein and Peptide Science, 15(4), 354-364. PubMed

15. Leuchte, H.H., Baezner, C., Baumgartner, R.A., Bevec, D., Bacher, G., Neurohr, C., & Behr, J. (2008). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. European Respiratory Journal, 32(5), 1289-1294. PubMed

16. Sarkar, D., Singh, S.K., & Kumar, A. (2024). Elevated vasoactive intestinal peptide in follicular fluid correlates with sympathetic dysregulation in polycystic ovary syndrome. Reproductive Biology and Endocrinology, 22(1), 18. PubMed

17. Moody, T.W., Gozes, I., & Said, S.I. (2011). VIP/PACAP in the context of radiopharmaceutical targeting of tumors. Current Pharmaceutical Design, 17(31), 3481-3491. PubMed

18. Shoemaker, R.C., & House, D.E. (2006). Sick building syndrome (SBS) and exposure to water-damaged buildings: Time series study, clinical trial and mechanisms. Neurotoxicology and Teratology, 28(5), 573-588. PubMed

19. Gonzalez-Rey, E., Varela, N., Chorny, A., & Delgado, M. (2007). Therapeutic approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Current Opinion in Pharmacology, 7(4), 429-436. PubMed

20. Waschek, J.A. (2013). VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair. British Journal of Pharmacology, 169(3), 512-523. PubMed